The Asia Pacific Pigmentation Disorder Treatment Market would witness market growth of 5.6% CAGR during the forecast period (2023-2030).
Skin pigmentation diseases are conditions that influence the natural pigmentation of the skin. Melanin is the pigment responsible for the colour of skin. It is produced by melanocytes, which are a type of skin cell. A variety of medical conditions may cause skin pigmentation disorders. Pigmentation disorders can manifest as hypopigmentation, depigmentation, or hyperpigmentation. In depigmentation, the pigment is eliminated, leaving behind colourless skin, whereas in hypopigmentation, it is diminished. Several conditions, including vitiligo, dark skin, and melasma, can cause skin pigmentation. Conditions characterized by hypopigmentation include vitiligo, pityriasis alba, tinea versicolor, and post-inflammatory hypopigmentation.
During the forecast period, the growth of the market is anticipated to be fuelled by the aging population. As aging skin becomes more avascular and causes the skin of older people to be more pronouncedly paler, for example, the senior population is more susceptible to certain pigmentation problems.
Many elderly individuals seek treatments to address signs of aging, including pigmentation disorders. There is a strong desire among the aging population in APAC to maintain a youthful appearance, including clear and even-toned skin. In some APAC countries, the aging population have higher disposable incomes, allowing them to invest in skincare and pigmentation disorder treatments. Some countries in the APAC region, such as South Korea and Thailand, have become popular destinations for medical tourism, including cosmetic and dermatological procedures. International patients seek treatment for pigmentation disorders while traveling to these countries. The development of the aging population in the APAC region presents opportunities for the market.
The China market dominated the Asia Pacific Pigmentation Disorder Treatment Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $86.8 million by 2030. The Japan market is registering a CAGR of 4.9% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 6.2% during (2023 - 2030).
Based on Type, the market is segmented into Vitiligo, Melasma, and Others. Based on Treatment, the market is segmented into Corticosteroids, Calcineurin Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, & Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
Skin pigmentation diseases are conditions that influence the natural pigmentation of the skin. Melanin is the pigment responsible for the colour of skin. It is produced by melanocytes, which are a type of skin cell. A variety of medical conditions may cause skin pigmentation disorders. Pigmentation disorders can manifest as hypopigmentation, depigmentation, or hyperpigmentation. In depigmentation, the pigment is eliminated, leaving behind colourless skin, whereas in hypopigmentation, it is diminished. Several conditions, including vitiligo, dark skin, and melasma, can cause skin pigmentation. Conditions characterized by hypopigmentation include vitiligo, pityriasis alba, tinea versicolor, and post-inflammatory hypopigmentation.
During the forecast period, the growth of the market is anticipated to be fuelled by the aging population. As aging skin becomes more avascular and causes the skin of older people to be more pronouncedly paler, for example, the senior population is more susceptible to certain pigmentation problems.
Many elderly individuals seek treatments to address signs of aging, including pigmentation disorders. There is a strong desire among the aging population in APAC to maintain a youthful appearance, including clear and even-toned skin. In some APAC countries, the aging population have higher disposable incomes, allowing them to invest in skincare and pigmentation disorder treatments. Some countries in the APAC region, such as South Korea and Thailand, have become popular destinations for medical tourism, including cosmetic and dermatological procedures. International patients seek treatment for pigmentation disorders while traveling to these countries. The development of the aging population in the APAC region presents opportunities for the market.
The China market dominated the Asia Pacific Pigmentation Disorder Treatment Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $86.8 million by 2030. The Japan market is registering a CAGR of 4.9% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 6.2% during (2023 - 2030).
Based on Type, the market is segmented into Vitiligo, Melasma, and Others. Based on Treatment, the market is segmented into Corticosteroids, Calcineurin Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, & Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type- Vitiligo
- Melasma
- Others
- Corticosteroids
- Calcineurin Inhibitor
- Others
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bausch Health Companies Inc
- Glenmark Pharmaceuticals Limited
- Obagi Cosmeceuticals LLC
- AbbVie, Inc.
- Dermavant Sciences, Inc. (Roivant Sciences Ltd.)
- Incyte Corporation
- Dr.Reddy’s Laboratories Ltd.
- Galderma S.A.
- Viatris, Inc. (Mylan N.V.)
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Pigmentation Disorder Treatment Market, By Type
Chapter 5. Asia Pacific Pigmentation Disorder Treatment Market, By Treatment
Chapter 6. Asia Pacific Pigmentation Disorder Treatment Market, By Distribution Channel
Chapter 7. Asia Pacific Pigmentation Disorder Treatment Market, By Country
Chapter 8. Company Profiles
Companies Mentioned
- Bausch Health Companies Inc
- Glenmark Pharmaceuticals Limited
- Obagi Cosmeceuticals LLC
- AbbVie, Inc.
- Dermavant Sciences, Inc. (Roivant Sciences Ltd.)
- Incyte Corporation
- Dr. Reddy’s Laboratories Ltd.
- Galderma S.A.
- Viatris, Inc. (Mylan N.V.)
- Pfizer, Inc.
Methodology
LOADING...
